Shanghai, China - The ceremony of Shanghai Science and Technology Progress Award 2022 was held on May 26. The project "Creation and Application of New Methods for Prostate Cancer Diagnosis and New Technologies for Precision Minimally Invasive Treatment" declared by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort^® MedBot^®) together with Renji Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, and Shanghai Jiading Central Hospital won the first prize of Science and Technology Progress Award, which is a full recognition of the scientific and technological innovation ability and academic level of MicroPort^® MedBot^®.

The Shanghai Science and Technology Progress Award is established by the Shanghai Municipal People's Government for rewarding significant scientific and technological achievements in scientific discoveries and original innovations in technological inventions, promoting changes in economic development and fostering strategic industries, improving urban safety, healthy ecological development and advancing innovation capacity and economic development in districts and counties. According to the Provisions of the Shanghai Municipality on Science and Technology (HFL No. 18), the Shanghai Science and Technology Award 2022 was granted to 316 projects (individuals) based on the review by the Municipal Science and Technology Award Review Committee, validation by the Municipal Science and Technology Award Committee, and approval by the Shanghai Municipal People's Government.

The project "Creation and Application of New Methods for Prostate Cancer Diagnosis and New Technologies for Precision Minimally Invasive Treatment" has addressed the core problems of prostate cancer diagnosis, treatment and mechanism investigation, provided new directions, and significantly improved the level of that in China.

Prostate cancer is one of the most common types among men in more than half of the world's countries. Economic development, increased life expectancy and lifestyle changes are driving a rapid increase in the incidence of prostate cancer in China. Up to now, one of the most common treatment options for prostate cancer is surgery, where the spread of cancer cells is stopped by removing the tumor from the prostate body. Minimally invasive surgery is a common choice. However, in the implementation of prostate cancer minimally invasive surgery, the small pelvic operation space leads to serious interference between the robotic arms and poor operational adaptability, which brings hidden dangers to the operation.

As the first Chinese-developed four-arm endoscopic robot approved by NMPA in China, Toumai^® four-arm endoscopic surgical robot has shown its own advantages in this project and brought much help to prostate cancer surgery.

First of all, Toumai^® has an independently developed "one-master-and-two-slave" suspension structure, which is obviously pioneering, enabling it to take up less space at the bedside and facilitating the operation by medical staff beside the bed. Such an layout is more adaptable to more surgical positioning needs. It also helps to reduce the interference by the robotic arm;

Secondly, Toumai^® allows for precise positioning in clinical surgical applications through advanced control methods pioneered in China.

Thirdly, a higher frequency of system control adapts to the precision, real-time requirements of robot-assisted radical prostate cancer surgery;

Fourthly, the 3D lumpectomy system of Toumai^® provides a high-definition, three-dimensional, realistic reproduction of the surgical field with smooth images, allowing the surgeon to identify anatomical structures more easily with reduced eye fatigue.

The first prize of Shanghai Science and Technology Progress Award is another recognition of MicroPort^® MedBot^®'s ability in its science and technology innovation. As the innovator and leader of home-made surgical robots, MicroPort^® MedBot^® has always been committed to independent innovation led by research and development. The group has by now made more than 1,000 patent applications and won the "Invention and Entrepreneurship Award - Innovation Award First Prize" issued by China Association of Inventions, and the highest award of "Super AI Leader" (SAIL) issued by the World Artificial Intelligence Conference.

Now the company's four products: Toumai^® Laparoscopic Surgery Robot, DFVision^® 3D Electronic Endoscope System and Honghu Orthopedic Surgical Robot, and Mona Lisa Prostate Puncture Robot Positioning System, have all been approved by the National Medical Products Administration. Among them, Honghu Orthopedic Surgical Robot has been certified by FDA, EU CE, and Brazilian ANVISA, making it first and only orthopedic surgery robot in China that holds certifications from four places.

MicroPort^® MedBot^® will continue to focus on technological innovation and application of surgical robots to serve medical professionals and benefit patients with affordable high-end surgical treatment solutions, in line with its original intention to "Make Surgery Easier, Safer and Less Invasive".